Zentalis Pharmaceuticals Inc. share price logo

Zentalis Pharmaceuticals Inc.

NASDAQ: ZNTL

Small Cap

$4.84

+0.23

(+4.99%)

as on

Zentalis Pharmaceuticals Inc. Stock Performance

as on July 1, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $4.45
    $5.11
    downward going graph

    8.06%

    Downside

    5.58%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $1.13
    $6.95
    downward going graph

    76.65%

    Downside

    43.60%

    Upside

    downward going graph

Zentalis Pharmaceuticals Inc. share price movements today

Previous Close
$4.61
Open
$4.60
Volume
2.1M
Day's Low - High
$4.45 - $5.11
52 Week Low - High
$1.13 - $6.95

Zentalis Pharmaceuticals Inc. Historical Returns

1 Month Return
+ 15.25 %
3 Month Return
+ 115.42 %
1 Year Return
+ 297.41 %
3 Year Return
-83.66 %
5 Year Return
-91.33 %

Zentalis Pharmaceuticals Inc. Stock Fundamentals & Key Indicators

Check Zentalis Pharmaceuticals Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$287.6M

EPS (TTM)

-1.736

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-141.5M

Revenue (TTM)

26.9M

Profit Margin

0.00%

Return On Equity TTM

-51.93%

Zentalis Pharmaceuticals Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Zentalis Pharmaceuticals Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Zentalis Pharmaceuticals Inc. image
Zentalis Pharmaceuticals Inc.
BUY$287.6M-91.33%NA0.00%NA
Revolution Medicines Inc. image
Revolution Medicines Inc.
BUY$38.7B506.87%NA0.00%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$38.9B73.15%73.0312.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$124.7B147.81%29.1635.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$66.4B13.12%15.4629.65%0.58%

Stock Returns calculator for Zentalis Pharmaceuticals Inc. Stock including INR - Dollar returns

The Zentalis Pharmaceuticals Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

Zentalis Pharmaceuticals Inc. investment value today

Current value as on today

₹4,60,864

Returns

₹3,60,864

(+360.86%)

Returns from Zentalis Pharmaceuticals Inc. Stock

₹3,17,241 (+317.24%)

Dollar Impact

₹43,623 (+43.62%)

Analyst Recommendation on Zentalis Pharmaceuticals Inc. Stock

Based on 17 analysts

BUY

82.35%

Buy

17.65%

Hold

0.00%

Sell

Based on 17 analysts, 82.35% of analysts recommend a 'BUY' rating for Zentalis Pharmaceuticals Inc.. Average target price of $6.5

Zentalis Pharmaceuticals Inc. Share Price Target

Get share price movements and forecasts by analysts on Zentalis Pharmaceuticals Inc..

What analysts predicted

25.54%UPSIDE

Target Price

$6.5

Current Price

$4.84

Analyzed by

17 Analysts

Target

$6.50

Zentalis Pharmaceuticals Inc. target price $6.5, a slight upside of 25.54% compared to current price of $4.84. According to 17 analysts rating.

Indian Investors' Interest in Zentalis Pharmaceuticals Inc. Stock

Search interest for Zentalis Pharmaceuticals Inc. Stock has decreased by -30% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-30% versus previous 30 day period

Zentalis Pharmaceuticals Inc. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
2
40
-
-
26
-
-
-
-
-
Gross Profit
1
40
0
0
26
0
0
-
0
0
Operating Income
-67
-24
-65
-51
-49
-45
-36
-33
-37
-37
EBITDA
-60
10
-87
-39
-45
-37
-34
-26
-34
-35
Interest Expense
5
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-61
10
-88
-40
-47
-48
-26
-26
-34
-35
Income Tax Expense
0
0
0
0
0
-
-
-
0
0
Net Income
-60
10
-88
-40
-47
-48
-26
-26
-35
-35
Net Profit Margin
-2895.29%
24.82%
0.00%
0.00%
-176.71%
0.00%
0.00%
0.00%
0.00%
0.00%

Zentalis Pharmaceuticals Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
-
-
-
-
-
67
-
Gross Profit
0
0
0
0
-1
-1
67
0
Operating Income
-23
-46
-118
-216
-227
-299
-191
-152
EBITDA
-23
-46
-118
-207
-233
-247
-186
-144
Interest Expense
-
1
2
110
2
-
-
-
Depreciation
0
0
0
0
1
1
1
0
Income Before Tax
-23
-46
-118
-166
-237
-292
-165
-136
Income Tax Expense
0
0
0
0
0
0
0
0
Net Income
-21
-45
-117
-158
-236
-292
-165
-137
Net Profit Margin
-150478.57%
0.00%
0.00%
0.00%
0.00%
0.00%
-245.96%
0.00%

Zentalis Pharmaceuticals Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
10
-88
-40
-47
-48
-26
-26
-35
-35
Operating Cash Flow
-51
-35
-44
-39
-32
-34
-26
-30
-32
Investing Cash Flow
61
34
48
32
40
30
28
32
30
Financing Cash Flow
0
0
0
-
0
-
0
-4
-1
Change in Cash
9
0
4
-7
8
-4
1
-3
-4

Zentalis Pharmaceuticals Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-46
-118
-166
-237
-292
-165
-137
Operating Cash Flow
-39
-86
-154
-163
-207
-170
-125
Investing Cash Flow
0
-284
-18
-114
-44
176
131
Financing Cash Flow
81
360
178
261
237
0
-4
Change in Cash
42
-11
6
-16
-14
5
2

Global Institutional Holdings in Zentalis Pharmaceuticals Inc.

Funds
Holdings
Matrix Capital Management Company, LLC
21.56%
PRIMECAP Management Company
1.34%
Morgan Stanley - Brokerage Accounts
1.16%
Connor Clark & Lunn Inv Mgmt Ltd
1.11%
Tybourne Capital Management (HK) Ltd
1.36%
See all

Insights on Zentalis Pharmaceuticals Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ZNTL stock has moved up by 25.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 423.6% return, outperforming this stock by 126.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 620.1% return, outperforming this stock by 703.8%

About Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
OrganisationZentalis Pharmaceuticals Inc.
Headquarters10275 Science Center Dr., San Diego, CA, United States, 92121
IndustryBiotechnology
CEOMs. Julie M. Eastland M.B.A.
E-voting on sharesClick here to vote

Key Management of Zentalis Pharmaceuticals Inc.

Name

Title

Mr. James B. Bucher J.D.

Chief Legal Officer & Corporate Secretary

Mr. Vincent A. Vultaggio

SVP of Finance & Principal Accounting Officer

Mr. Robert J. DiVasto P.E.

Chief Technical Officer

Ms. Wendy Chang

Chief People Officer

Ms. Sarah Kelly

Senior Vice President of Commercial Strategy

Ms. Julie M. Eastland M.B.A.

CEO, President & Director

Dr. Ingmar Bruns M.D., Ph.D.

Chief Medical Officer

Mr. Haibo Wang

Chief Business Officer

Mr. Rajesh Israni

Executive VP of Regulatory Affairs & Medical Writing

Mr. Henry Gu

Senior VP & Head of Intellectual Property

FAQs

What is Zentalis Pharmaceuticals Inc. share price today?

Zentalis Pharmaceuticals Inc. share price today is $4.84 as on at the close of the market. Zentalis Pharmaceuticals Inc. share today touched a day high of $5.11 and a low of $4.45.

What is the 52 week high and 52 week low for Zentalis Pharmaceuticals Inc. share?

Zentalis Pharmaceuticals Inc. share touched a 52 week high of $6.95 on and a 52 week low of $1.13 on . Zentalis Pharmaceuticals Inc. stock price today i.e. is closed at $4.84,which is 30.36% down from its 52 week high and 328.32% up from its 52 week low.

What is Zentalis Pharmaceuticals Inc.'s market capitalisation today?

Zentalis Pharmaceuticals Inc. market capitalisation is $0.00T as on .

How to invest in Zentalis Pharmaceuticals Inc. Stock (ZNTL) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Zentalis Pharmaceuticals Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Zentalis Pharmaceuticals Inc. Shares that will get you 0.3099 shares as per Zentalis Pharmaceuticals Inc. share price of $4.84 per share as on July 1, 2026 at 1:29 am IST.

What is the minimum amount required to buy Zentalis Pharmaceuticals Inc. Stock (ZNTL) from India?

Indian investors can start investing in Zentalis Pharmaceuticals Inc. (ZNTL) shares with as little as ₹94.66 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹946.60 in Zentalis Pharmaceuticals Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Zentalis Pharmaceuticals Inc. share’s latest price of $4.84 as on July 1, 2026 at 1:29 am IST, you will get 2.0661 shares of Zentalis Pharmaceuticals Inc.. Learn more about fractional shares .

What are the returns that Zentalis Pharmaceuticals Inc. has given to Indian investors in the last 5 years?

Zentalis Pharmaceuticals Inc. stock has given -91.33% share price returns and 27.14% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?